abemaciclib + nonsteroidal aromatase inhibitor

Abemaciclib + nonsteroidal aromatase inhibitor is a **combination therapy** used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) breast cancer, both in advanced/metastatic and early (adjuvant) settings[1][2][3][4]. **Abemaciclib** is a selective, orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which prevents phosphorylation of the retinoblastoma protein (Rb), resulting in G1 cell cycle arrest and inhibition of cancer cell proliferation. **Nonsteroidal aromatase inhibitors** (letrozole, anastrozole) inhibit the aromatase enzyme, reducing estrogen synthesis, thus depriving HR+ breast cancers of estrogen-driven growth signals. The combination increases antitumor activity and has shown improved progression-free survival and invasive disease-free survival in clinical trials, especially in high-risk early breast cancer populations. Common adverse effects include diarrhea, fatigue, neutropenia, nausea, and hepatotoxicity[1][2][3][4][5].

Brand names

Verzenio + Arimidex + Femara

Other names

abemaciclib plus NSAIabemaciclib + letrozoleabemaciclib + anastrozoleabemaciclib plus nonsteroidal aromatase inhibitor